Zydus Cadila has received the tentative approval from the US Food and Drug Administration (USFDA) to market Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, (US RLD-JANUMET XR), 50 mg/500 mg, 50 mg/ 1,000 mg and 100 mg/ 1,000 mg.
It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. It contains two oral antidiabetic medications used in the management of type 2 diabetes -Sitagliptin and metformin hydrochloride extended-release.
The group now has 255 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1525.30 |
Dr. Reddys Lab | 6256.55 |
Cipla | 1419.45 |
Zydus Lifesciences | 973.70 |
Lupin | 1649.90 |
View more.. |